Climb Bio, Inc. Common Stock

CLYMNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
13.08 USD
↗ 0.42 (3.32%)AT CLOSE (11:59 AM EDT)
13.12
↗ 0.04 (0.31%)
POST MARKET (AS OF 06:48 PM EDT)
Post Market
AS OF 06:48 PM EDT
13.12
↗ 0.04 (0.31%)
🔴Market: CLOSED

Shares of Climb Bio, Inc. Common Stock (CLYM) are trading at $13.08. Our models show a "Strong Buy" technical signal alongside a "Neutral" fundamental rating. Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. CLYM is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Jun 26, 2026.

Open?$12.51
High?$13.16
Low?$12.42
Prev. Close?$12.66
Volume?6.3M
Avg. Volume?1.3M
VWAP?$12.75
Rel. Volume?4.86x
Bid / Ask
Bid?$9.03 × 100
Ask?$15.29 × 100
Spread?$6.26
Midpoint?$12.16
Valuation & Ratios
Market Cap?749.0M
Shares Out?57.3M
Float?20.0M
Float %?41.8%
P/E Ratio?N/A
P/B Ratio?5.06
EPS?-$0.92
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
Themes
Biotech - Drug Development›Immunology & AutoimmuneBiotech - Drug Development›Rare Disease Therapeutics
Employees
29
Market Cap
724.9M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.climbbio.com
Listed
2021-08-10
Address
20 WILLIAM STREET
WELLESLEY HILLS, MA 02481
Phone: 1-866-857-2596
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
28
Piotroski F-Score?0/9Weak
Altman Z-Score?101.60Safe
Confidence?41%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?15.04%High
Short Interest?3.0M
Days to Cover?2.0
Free Float20.0M
Avg Daily Volume1.5M
Settlement Date2026-06-15
Financial Health
Current Ratio?27.86Strong
Quick Ratio?27.86Strong
Cash Ratio?2.05Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
36
5.06FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-12.4CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
5
-35.7%WEAK▾
ROA?
S&P
3
-34.7%WEAK▾
Cash Flow & Enterprise
FCF?$-53487000
Enterprise Value?$740.6M
Fundamentals ratios updated end of day
MarketsMoversWatchlist